Skip to main content
Erschienen in: Journal of Bioethical Inquiry 1/2020

03.01.2020 | Original Research

Beyond Mendelian Genetics: Anticipatory Biomedical Ethics and Policy Implications for the Use of CRISPR Together with Gene Drive in Humans

verfasst von: Michael W. Nestor, Richard L. Wilson

Erschienen in: Journal of Bioethical Inquiry | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR) genome editing has already reinvented the direction of genetic and stem cell research. For more complex diseases it allows scientists to simultaneously create multiple genetic changes to a single cell. Technologies for correcting multiple mutations in an in vivo system are already in development. On the surface, the advent and use of gene editing technologies is a powerful tool to reduce human suffering by eradicating complex disease that has a genetic etiology. Gene drives are CRISPR mediated alterations to genes that allow them to be passed on to subsequent populations at rates that approach one hundred per cent transmission. Therefore, from an anticipatory biomedical ethics perspective, it is possible to conceive gene drive being used with CRISPR to permanently ameliorate aberrant genes from wild-type populations containing mutations. However, there are also a number of possible side effects that could develop as the result of combining gene editing and gene drive technologies in an effort to eradicate complex diseases. In this paper, we critically analyse the hypothesis that the combination of CRISPR and gene drive will have a deleterious effect on human populations from an ethical perspective by developing an anticipatory ethical analysis of the implications for the use of CRISPR together with gene drive in humans.
Literatur
Zurück zum Zitat Akcakaya, P., M.L. Bobbin, J.A. Guo, et al. 2018. In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature 561(7723): 416-419.PubMedPubMedCentral Akcakaya, P., M.L. Bobbin, J.A. Guo, et al. 2018. In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature 561(7723): 416-419.PubMedPubMedCentral
Zurück zum Zitat Allhoff, F., A. Henschke, and B.J. Strawser. 2016. Binary bullets: the ethics of cyberwarfare. New York: Oxford University Press. Allhoff, F., A. Henschke, and B.J. Strawser. 2016. Binary bullets: the ethics of cyberwarfare. New York: Oxford University Press.
Zurück zum Zitat Andreasen, N.C. 2008. The relationship between creativity and mood disorders. Dialogues in Clinical Neuroscience 10(2): 251-255.PubMedPubMedCentral Andreasen, N.C. 2008. The relationship between creativity and mood disorders. Dialogues in Clinical Neuroscience 10(2): 251-255.PubMedPubMedCentral
Zurück zum Zitat Audi, R. 2007. Moral value and human diversity. Oxford University Press. Audi, R. 2007. Moral value and human diversity. Oxford University Press.
Zurück zum Zitat Babar, M.I., M. Ghazali, D.N. Jawawi, and K. Bin Zaheer. 2015. StakeMeter: vValue-based stakeholder identification and quantification framework for value-based software systems. PLoS One 10(3): e0121344.PubMedPubMedCentral Babar, M.I., M. Ghazali, D.N. Jawawi, and K. Bin Zaheer. 2015. StakeMeter: vValue-based stakeholder identification and quantification framework for value-based software systems. PLoS One 10(3): e0121344.PubMedPubMedCentral
Zurück zum Zitat Cong, L., F.A. Ran, D. Cox, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121): 819-823.PubMedPubMedCentral Cong, L., F.A. Ran, D. Cox, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121): 819-823.PubMedPubMedCentral
Zurück zum Zitat Cuilla, J., C. Martin, and R.C. Solomon. 2007. Honest business, a business ethics reader. New York: Oxford University Press. Cuilla, J., C. Martin, and R.C. Solomon. 2007. Honest business, a business ethics reader. New York: Oxford University Press.
Zurück zum Zitat Esvelt K.M, A.L. Smidler, F. Catteruccia, and G.M. Church. 2014. Concerning RNA-guided gene drives for the alteration of wild populations. Elife, 3. Esvelt K.M, A.L. Smidler, F. Catteruccia, and G.M. Church. 2014. Concerning RNA-guided gene drives for the alteration of wild populations. Elife, 3.
Zurück zum Zitat Fu, Y., J.A. Foden, C. Khayter, et al. 2013. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnology 31(9): 822-826.PubMedPubMedCentral Fu, Y., J.A. Foden, C. Khayter, et al. 2013. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnology 31(9): 822-826.PubMedPubMedCentral
Zurück zum Zitat Gulati, S. 2008. Technology-enhanced learning in developing nations: A review. The International Review of Research in Open and Distributed Learning 9(1): 1-8. Gulati, S. 2008. Technology-enhanced learning in developing nations: A review. The International Review of Research in Open and Distributed Learning 9(1): 1-8.
Zurück zum Zitat Hester, K., M. Mullins, F. Murphy, and S.A.M. Tofail. 2015. Anticipatory ethics and governance (AEG): Towards a future care orientation around nanotechnology. NanoEthics 9(2): 123-136. Hester, K., M. Mullins, F. Murphy, and S.A.M. Tofail. 2015. Anticipatory ethics and governance (AEG): Towards a future care orientation around nanotechnology. NanoEthics 9(2): 123-136.
Zurück zum Zitat Jasanoff, S., and J.B. Hurlbut. 2018. A global observatory for gene editing. Nature 555(7697) 435-437.PubMed Jasanoff, S., and J.B. Hurlbut. 2018. A global observatory for gene editing. Nature 555(7697) 435-437.PubMed
Zurück zum Zitat Jasanoff, S, J.B. Hurlbut, and K. Saha. 2015. CRISPR democracy: Gene editing and the need for inclusive deliberation. Issues in Science and Technology 32(1): 37. Jasanoff, S, J.B. Hurlbut, and K. Saha. 2015. CRISPR democracy: Gene editing and the need for inclusive deliberation. Issues in Science and Technology 32(1): 37.
Zurück zum Zitat Liang, P., Y. Xu, X. Zhang, et al. 2015. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6(5): 363-372.PubMedPubMedCentral Liang, P., Y. Xu, X. Zhang, et al. 2015. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6(5): 363-372.PubMedPubMedCentral
Zurück zum Zitat Ma, H., N. Marti-Gutierrez., S.W. Park, et al. 2017. Correction of a pathogenic gene mutation in human embryos. Nature 548(7668): 413-419.PubMed Ma, H., N. Marti-Gutierrez., S.W. Park, et al. 2017. Correction of a pathogenic gene mutation in human embryos. Nature 548(7668): 413-419.PubMed
Zurück zum Zitat Nestor, M.W., E. Artimovich, and R.L. Wilson. 2014. The ethics of gene editing technologies in human stem cells. Ethics in Biology, Engineering and Medicine: An International Journal 5(4): 323-338. Nestor, M.W., E. Artimovich, and R.L. Wilson. 2014. The ethics of gene editing technologies in human stem cells. Ethics in Biology, Engineering and Medicine: An International Journal 5(4): 323-338.
Zurück zum Zitat Nestor, M.W., and R.L. Wilson. 2018. Can the Use of CRISPR in humans result in decreased social justice for future stakeholders? Ethics in Biology, Engineering and Medicine: An International Journal 9(1): 5-16. Nestor, M.W., and R.L. Wilson. 2018. Can the Use of CRISPR in humans result in decreased social justice for future stakeholders? Ethics in Biology, Engineering and Medicine: An International Journal 9(1): 5-16.
Zurück zum Zitat Normile, D. 2018. Shock greets claim of CRISPR-edited babies. Science 362(6418): 978-979.PubMed Normile, D. 2018. Shock greets claim of CRISPR-edited babies. Science 362(6418): 978-979.PubMed
Zurück zum Zitat Oye, K.A., K. Esvelt, E. Appleton, et al. 2014. Biotechnology. Regulating gene drives. Science 345(6197): 626-628.PubMed Oye, K.A., K. Esvelt, E. Appleton, et al. 2014. Biotechnology. Regulating gene drives. Science 345(6197): 626-628.PubMed
Zurück zum Zitat Polcz, S., and A. Lewis. 2016. CRISPR-Cas9 and the non-germline non-controversy. Journal of Law and the Biosciences 3(2): 413-425. Polcz, S., and A. Lewis. 2016. CRISPR-Cas9 and the non-germline non-controversy. Journal of Law and the Biosciences 3(2): 413-425.
Zurück zum Zitat Schaefer, K.A.,W.-H. Wu, D.F. Colgan, S.H. Tsang, A.G. Bassuk, and V.B. Mahajan. 2017. Unexpected mutations after CRISPR–Cas9 editing in vivo. Nature Methods 14(6): 547.PubMedPubMedCentral Schaefer, K.A.,W.-H. Wu, D.F. Colgan, S.H. Tsang, A.G. Bassuk, and V.B. Mahajan. 2017. Unexpected mutations after CRISPR–Cas9 editing in vivo. Nature Methods 14(6): 547.PubMedPubMedCentral
Zurück zum Zitat Schwank, G., B.K. Koo, V. Sasselli, et al. 2013. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13(6): 653-658.PubMed Schwank, G., B.K. Koo, V. Sasselli, et al. 2013. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13(6): 653-658.PubMed
Zurück zum Zitat Smith, C., L. Abalde-Atristain, C. He, et al. 2015. Efficient and allele-specific genome editing of disease loci in human iPSCs. Molecular Therapy 23(3): 570-577.PubMed Smith, C., L. Abalde-Atristain, C. He, et al. 2015. Efficient and allele-specific genome editing of disease loci in human iPSCs. Molecular Therapy 23(3): 570-577.PubMed
Zurück zum Zitat Sun, N., and H. Zhao. 2014. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnology and Bioengineering 111(5): 1048-1053.PubMed Sun, N., and H. Zhao. 2014. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnology and Bioengineering 111(5): 1048-1053.PubMed
Zurück zum Zitat Wang, H., M. La Russa, and L.S. Qi. 2016. CRISPR/Cas9 in genome editing and beyond. Annual Review of Biochemistry 85: 227-264.PubMed Wang, H., M. La Russa, and L.S. Qi. 2016. CRISPR/Cas9 in genome editing and beyond. Annual Review of Biochemistry 85: 227-264.PubMed
Zurück zum Zitat Werhane, P.H. 2002. Moral imagination and systems thinking. Journal of Business Ethics 38(1-2): 33-42. Werhane, P.H. 2002. Moral imagination and systems thinking. Journal of Business Ethics 38(1-2): 33-42.
Zurück zum Zitat Xie, F., L. Ye, J.C. Chang, et al. 2014. Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Research 24(9): 1526-1533.PubMedPubMedCentral Xie, F., L. Ye, J.C. Chang, et al. 2014. Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Research 24(9): 1526-1533.PubMedPubMedCentral
Zurück zum Zitat Yin, H., W. Xue, S. Chen, et al. 2014. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology 32(6): 551-553.PubMedPubMedCentral Yin, H., W. Xue, S. Chen, et al. 2014. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology 32(6): 551-553.PubMedPubMedCentral
Metadaten
Titel
Beyond Mendelian Genetics: Anticipatory Biomedical Ethics and Policy Implications for the Use of CRISPR Together with Gene Drive in Humans
verfasst von
Michael W. Nestor
Richard L. Wilson
Publikationsdatum
03.01.2020
Verlag
Springer Singapore
Erschienen in
Journal of Bioethical Inquiry / Ausgabe 1/2020
Print ISSN: 1176-7529
Elektronische ISSN: 1872-4353
DOI
https://doi.org/10.1007/s11673-019-09957-7

Weitere Artikel der Ausgabe 1/2020

Journal of Bioethical Inquiry 1/2020 Zur Ausgabe

Editorial

Cui Bono?